Skip to main content
MOLN
NASDAQ Life Sciences

Molecular Partners Provides Broad Clinical Pipeline Update: MP0712 Data Expected Soon, MP0726 FIH in H2

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.99
Mkt Cap
$160.478M
52W Low
$3.41
52W High
$5.36
52W Position info
17% above low
Off High info
26% below high
Rel. Volume info
4.6× avg
Market data snapshot near publication time

MOLN sits 17% above its 52-week low of $3.41 on elevated volume (4.6× avg).

Summary

Molecular Partners provided a comprehensive update on its radiotherapeutic pipeline, including anticipated initial data for MP0712, planned first-in-human imaging for MP0726, and new pipeline expansion initiatives.


Key Events · Product Development and Regulatory · MOLN

  • MP0712 Clinical Progress Update

    Dosing is ongoing in the Phase 1/2a trial for MP0712, a DLL3-targeted Radio-DARPin. Initial data is expected within the coming months, with comprehensive efficacy data anticipated in 2027.

  • New Compassionate Care Program Initiated

    A DLL3-targeting Radio-DARPin (MP0714) is now being utilized in a compassionate care program in South Africa, highlighting the versatility of DARPins as isotope-agnostic vectors.

  • MP0726 First-in-Human Imaging Planned

    First-in-human imaging for MP0726, a Radio-DARPin targeting mesothelin (MSLN), is planned to commence in the second half of 2026.

  • Pipeline Expansion and Future INDs

    The company plans to nominate a new radiotherapeutic target in the second half of 2026 and file two Investigational New Drug (IND) applications across its portfolio in 2027.


Analysis · MOLN · Life Sciences

This filing provides a significant update on Molecular Partners' core radiotherapeutic pipeline, detailing progress for its lead candidate MP0712, including timelines for initial clinical data. The initiation of a compassionate care program for MP0714 demonstrates the flexibility of their DARPin platform. Furthermore, the advancement of MP0726 to first-in-human imaging and the planned new target nominations and INDs signal a robust and expanding development pipeline, which is critical for a clinical-stage biotech company.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MOLN was trading at $3.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $160.5M. The 52-week trading range was $3.41 to $5.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MOLN - Latest Insights

MOLN
Oct 29, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.71
Real-time Price: $2.94 info
Change: -$0.7699 (-21%) info
Market Cap: $115.959M info
MOLN
Aug 25, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.40
Real-time Price: $2.94 info
Change: -$1.46 (-33%) info
Market Cap: $115.959M info
MOLN
Jul 16, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.91
Real-time Price: $2.94 info
Change: -$0.970 (-25%) info
Market Cap: $115.959M info
MOLN
Jul 02, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.93
Real-time Price: $2.94 info
Change: -$0.990 (-25%) info
Market Cap: $115.959M info
MOLN
May 12, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $2.94 info
Change: -$1.10 (-27%) info
Market Cap: $115.959M info